Warning on risks: Financial contracts for difference are complex instruments and are associated with a high risk of rapid financial losses due to leverage. On 72.76% of retail investor accounts, financial losses occur when trading financial contracts for difference with this provider. You should consider whether you understand how financial contracts for difference work, and whether you can afford to take the high risk of suffering financial losses. Please read the Risk Disclosures.

Market analysis and news

Get an overview of current market developments with regular analysis from our analysts. We offer a detailed view of key events, economic indicators and investment opportunities. Follow the development of the markets with us and make decisions based on data and experience.

26/1/2022

Development of new broad-spectrum vaccines: Novavax and Valneva

Vaccines from Novavax and Valneva have a promising future, according to preliminary estimates. Several countries are showing interest and approving the newest vaccines on the market, also due to the spread of the Omikron mutation, which is up to 3 times more contagious than Delta. Scientists even claim that there are other mutations. Some countries are already making vaccination compulsory or bringing in tougher measures for the unvaccinated as the situation in hospitals worsens.

20/12/2021

The second year of covid: China's economy is recovering best, followed by the United States ahead of the European Union

For the second year in a row, the global economy is struggling to cope with the negative effects of the coronavirus pandemic. According to Ozios' analysis, China is doing best among the world's largest economic centres. Its growth this year may climb to the pace that the world's most populous country was used to at the beginning of the last decade. The United States has already surpassed the pre-pandemic level, and the European Union is likely to do so next year.

18/11/2021

The Vaccine Victors – Where are They Now?

With the rise of COVID-19, vaccine makers fought in the pharmaceutical battleground, to gain national trust for its vaccine effectiveness and safety. The outbreak of the coronavirus pandemic incentivized multiple companies to develop vaccines, including Novavax, Sputnik and GlaxoSmithKline (GSK), but generally speaking, four vaccine makers came out on top to mass produce COVID-19 immunization; Johnson & Johnson, Pfizer/BioNTech, Moderna and AstraZeneca. But, how are the vaccine victors performing lately, now that COVID-19 has hit the brakes?

1/11/2021

Will the global economy recover from the effects of the pandemic?

It will soon be two years since the outbreak of the COVID-19 virus. Despite the development of new vaccines and the efforts of a global approach to vaccination, many are still wondering what the recovery of the global economy might look like and whether it can recover from a pandemic. However, its outlook does not look ideal yet. The International Monetary Fund (IMF) lowered its July forecast of global economic growth to 5.9 percent in 2021 in its October World Economic Outlook report, and the outlook for 2022 remains at the same level, namely 4.9 percent.

Latest analyses